Block-LC SGB Treatment Trial
Open the official record
This page only displays public information reproduced from the official ClinicalTrials.gov record NCT07947901. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Block-LC: A Phase 2 Randomized, Single-blind, Sham-controlled Trial to Evaluate the Quality of Life and Symptom Severity After Stellate Ganglion Block Procedure in Persons 18-65 Years With Long COVID, Followed by a Sham-to-active Open Label Extension
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study is a randomized, single-blind, sham-controlled trial to assess the efficacy and safety of a series of two sets (four total) of bilateral Study Procedures (SGB or Sham) administered to adults with Long COVID (Figure 1) followed by a sham-to-active OLE trial. Approximately 272 (136 per arm) participants will be randomized 1:1 to receive SGB or a sham Study Procedure. Following screening and completion of baseline PROs, eligible participants will undergo in-person baseline assessments and blood draw. Those who are confirmed to be eligible will complete a pre-procedure telehealth visit and then be randomized 1:1 at Day 1 to receive either active SGB (Arm 1) or sham (Arm 2); each administration is referred to as a "Study Procedure". Participants will receive a total of four Study Procedures with follow up visits to assess recovery. Outcomes will be assessed at 28 days, 56 days, 12 weeks, and 26 weeks. Follow-up visits at weeks 12 and 26 allow for assessment of durability of response and delayed adverse events (AEs). The primary objective is to compare the change in overall HRQoL from baseline to 8 weeks between participants aged 18-65 years with Long COVID randomized to a series of two sets of bilateral SGB or sham Study Procedures.
Study identification
- NCT ID
- NCT07947901
- Recruitment status
- Not yet recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 272 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 65 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 9, 2026 (Estimated)
- Primary completion
- Apr 9, 2029 (Estimated)
- Completion
- Apr 9, 2029 (Estimated)
- Last update posted
- Nov 19, 2026
2026 – 2029
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Oregon Health and Science University | Portland | Oregon | 97239-3011 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07947901, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 19, 2026 · Synced Nov 19, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.